Effector-mediated eradication of precursor B acute lymphoblastic leukemia with a novel Fc-engineered monoclonal antibody targeting the BAFF-R

Molecular Cancer Therapeutics

Volumn 13, Issue 6, 2014, Pages 1567-1577

  Parameswaran, Reshmi ^a,e   Lim, Min ^a,f   Fei, Fei ^a   Abdel Azim, Hisham ^a   Arutyunyan, Anna ^a   Schiffer, Isabelle ^a   McLaughlin, Margaret E ^c   Gram, Hermann ^d   Huet, Heather ^c   Groffen, John ^a,b   Heisterkamp, Nora ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

^f Novartis Vaccines and Diagnostics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; CD16 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B 1239; NILOTINIB; UNCLASSIFIED DRUG; IMMUNOGLOBULIN FC FRAGMENT; TNFRSF13C PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ARTICLE; BONE MARROW; CELL KILLING; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG TARGETING; EFFECTOR CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; KILLER CELL; MACROPHAGE; MOUSE; NOD SCID GAMMA MOUSE; NONHUMAN; PHAGOCYTOSIS; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN; STROMA CELL; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; B-CELL ACTIVATION FACTOR RECEPTOR; CELL LINE, TUMOR; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOTHERAPY; MICE; MOLECULAR TARGETED THERAPY; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84902659309     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-1023     Document Type: Article

References (24)

1. Parameswaran R, Muschen M, Kim YM, Groffen J, Heisterkamp N. A functional receptor for B-cell-activating factor is expressed on human acute lymphoblastic leukemias. Cancer Res 2010;70:4346-56.
2. Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003;21:231-64. (Pubitemid 37174532)
3. Lyu MA, Cheung LH, Hittelman WN, Marks JW, Aguiar RC, Rosenblum MG. The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA. Mol Cancer Ther 2007;6:460- 70.
4. Kern C, Cornuel JF, Billard C, Tang R, Rouillard D, Stenou V, et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 2004;103:679-88. (Pubitemid 38145555)
5. Asselin BL, Gaynon P, Whitlock JA. Recent advances in acute lymphoblastic leukemia in children and adolescents: an expert panel discussion. Curr Opin Oncol 2013;25 Suppl 3:S1-13; quiz S4-6.
6. Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2002;2:465-75. (Pubitemid 37328738)
7. Khan WN. B cell receptor and BAFF receptor signaling regulation of B cell homeostasis. J Immunol 2009;183:3561-7.
8. Smith SH, Cancro MP. Cutting edge: B cell receptor signals regulate BLyS receptor levels in matureBcells and their immediate progenitors. J Immunol 2003;170:5820-3. (Pubitemid 36682559)
9. Maia S, Pelletier M, Ding J, Hsu YM, Sallan SE, Rao SP, et al. Aberrant expression of functional BAFF-system receptors by malignant B-cell precursors impacts leukemia cell survival. PLoS ONE 2011;6:e20787.
10. Onda K, Iijima K, Katagiri YU, Okita H, Saito M, Shimizu T, et al. Differential effects of BAFF on B cell precursor acute lymphoblastic leukemia and Burkitt lymphoma. Int J Hematol 2010;91:808-19.
11. Parameswaran R, Yu M, Lyu MA, Lim M, Rosenblum MG, Groffen J, et al. Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin. Leukemia 2012;26:1786-96.
12. Mathisen MS, Kantarjian HM, Jabbour EJ. Emerging drugs for acute lymphocytic leukemia. Expert Opin Emerg Drugs 2014;19:37-50.
13. Rytting M, Triche L, Thomas D, O'Brien S, Kantarjian H. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia. Pediatr Blood Cancer 2014;61:369-72.
14. Shah NN, Dave H, Wayne AS. Immunotherapy for pediatric leukemia. Front Oncol 2013;3:166.
15. Natsume A, Niwa R, Satoh M. Improving effector functions of antibodies for cancer treatment: enhancing ADCC and CDC. Drug Des Devel Ther 2009;3:7-16.
16. Hoelzer D. Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia. Curr Opin Oncol 2013;25:701-6.
17. Daver N, O'Brien S. Novel therapeutic strategies in adult acute lymphoblastic leukemia-a focus on emerging monoclonal antibodies. Curr Hematol Malig Rep 2013;8:123-31.
18. Matlawska-Wasowska K, Ward E, Stevens S, Wang Y, Herbst R, Winter SS, et al. Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies. Leukemia 2013;27:1263-74.
19. Lee CV, Hymowitz SG, Wallweber HJ, Gordon NC, Billeci KL, Tsai SP, et al. Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells. Blood 2006;108:3103-11.
20. Beck A, Reichert JM. Marketing approval of mogamulizumab: a triumph for glyco-engineering. MAbs 2012;4:419-25.
21. Fei F, Stoddart S, Muschen M, Kim YM, Groffen J, Heisterkamp N. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia. Leukemia 2010;24:813-20.
22. Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, et al. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature 2011;473:384-8.
23. Davies JQ, Gordon S. Isolation and culture of human macrophages. Methods Mol Biol 2005;290:105-16.
24. Pillay V, Gan HK, Scott AM. Antibodies in oncology. N Biotechnol 2011;28:518-29.